Enara Bio Expands Leadership, Accelerates T-Cell Programs
01 May 2025 //
GLOBENEWSWIRE
Enara Bio Gets $32.5M Series B For Dark Antigens® TCR Pipeline
03 Oct 2024 //
GLOBENEWSWIRE
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio
04 Jan 2024 //
GLOBENEWSWIRE
Enara Bio, ROME & Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
01 Nov 2023 //
GLOBENEWSWIRE
Enara Bio highlights Dark Antigens as a novel class of targets
07 Nov 2022 //
PRNEWSWIRE
ROME & Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry
02 Nov 2022 //
BUSINESSWIRE
Enara Bio and Collaborators Present Progress of MR1-targeted T-Cell Therapies
09 May 2022 //
PRNEWSWIRE